Transdermal Rotigotine Improves Sleep Fragmentation in Parkinson’s Disease: Results of the Multicenter, Prospective SLEEP-FRAM Study

Table 2

Parkinson’s Disease Sleep Scale (PDSS) subscale scores at baseline and 3 months in patients with Parkinson’s disease receiving rotigotine.

PDSS subscale score	Baseline	3 months	value
Sleep maintenance	3.4 ± 0.9	1.9 ± 1.4	< 0.0001
Nocturnal motor symptoms	6 ± 5	3 ± 3	< 0.0001
Sleep efficiency	4.3 ± 2	2.3 ± 2	< 0.0001
Restless legs-like symptoms	2.5 ± 2	1.4 ± 2	< 0.005
Nocturia	3.6 ± 0.9	3.0 ± 1.0	< 0.004